BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/9/2016 9:12:00 AM | Browse: 729 | Download: 934
 |
Received |
|
2016-06-15 14:28 |
|
Peer-Review Started |
|
2016-06-27 13:50 |
|
To Make the First Decision |
|
2016-07-27 08:20 |
|
Return for Revision |
|
2016-07-30 15:57 |
|
Revised |
|
2016-09-26 17:24 |
|
Second Decision |
|
2016-09-30 11:17 |
|
Accepted by Journal Editor-in-Chief |
|
2016-10-02 18:39 |
|
Accepted by Company Editor-in-Chief |
|
2016-10-18 16:53 |
|
Articles in Press |
|
2016-10-18 16:53 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-11-11 10:05 |
|
Publish the Manuscript Online |
|
2016-12-09 09:12 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ananthi Anandhakrishnan and Márta Korbonits |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Márta Korbonits, Professor of Endocrinology and Metabolism, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6 BQ,
United Kingdom. m.korbonits@qmul.ac.uk |
| Key Words |
Obesity pathophysiology; Glucagon-like peptide 1 analogues; Glucagon-like peptide 1; Clinical obesity |
| Core Tip |
Several lines of clinical evidence implicate an important functional role for glucagon-like peptide 1 (GLP-1) signalling in the pathophysiology of clinical obesity. Here we critically evaluate such findings in way that as yet has been unexplored; using the well established roles of GLP-1 as an incretin and meal to meal satiety signal to go some way toward explaining findings from interventional and observational clinical data that suggest functional deficits of GLP-1 to be a contributor to the obesity phenotype. We also explore the promise shown by GLP-1 analogues in achieving and maintaining significant weight loss in obese individuals, and use findings to discuss to what extent they too may support a role for GLP-1 in obesity pathophysiology. We conclude by exploring what an association with functional GLP-1 deficit could mean for the clinical management of obesity; conducting cost and risk benefit analyses to evaluate the extent to which GLP-1 analogues may provide a successful and sustainable option for the medical management of obesity that remains as yet, an unmet clinical need. |
| Publish Date |
2016-12-09 09:12 |
| Citation |
Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598 |
| URL |
http://www.wjgnet.com/1948-9358/full/v7/i20/572.htm |
| DOI |
http://dx.doi.org/10.4239/wjd.v7.i20.572 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
